This study analyzed binding and neutralizing antibody titers up to 6 months after standard vaccination with BNT162b2 (two doses of 30 µg each) in SARS-CoV-2 naïve patients (n = 59) on hemodialysis. Humoral vaccine responses were measured before and 6, 12, and 24 weeks after the first vaccination. A chemiluminescent immunoassay (CLIA) was used to quantify SARS-CoV-2 IgG against the spike glycoprotein. SARS-CoV-2 neutralizing activity was tested against the wild-type virus. A multivariable binary regression model was used to identify risk factors for the absence of humoral immune responses at 6 months. At week 6, vaccine-specific seroconversion was detected in 96.6% of all patients with median anti-SARS-CoV-2 IgGs of 918 BAU/mL. At weeks 12 and 24, seroconversion rates decreased to 91.5% and 79.7%, and corresponding median binding antibody titers declined to 298 BAU/mL and 89 BAU/mL, respectively. Neutralizing antibodies showed a decay from 79.6% at week 6 to 32.8% at week 24. The risk factor with the strongest association for vanishing immune responses was low serum albumin ( p = 0.018). Regarding vaccine-specific humoral responses 6 months after the standard BNT162b2 vaccination schedule, SARS-CoV-2 naïve patients receiving hemodialysis must be considered at risk of becoming infected with SARS-CoV-2 and being infectious.
【저자키워드】 COVID-19, Neutralizing antibodies, Chronic kidney disease, mRNA vaccines, BNT162b2, Hemodialysis, anti-SARS-CoV-2 IgG, 【초록키워드】 CLIA, SARS-CoV-2, immune response, vaccination, antibody, spike glycoprotein, risk, risk factor, Neutralizing activity, Seroconversion, Humoral response, vaccine response, Regression model, Patient, humoral immune response, chemiluminescent immunoassay, serum albumin, SARS-CoV-2 IgG, Neutralizing antibody titer, binding, association, dose, binding antibody, naïve, wild-type virus, seroconversion rate, first vaccination, vaccination schedule, multivariable, analyzed, identify, was used, receiving, median, absence, were measured, declined, infected with SARS-CoV-2, vanishing, was tested, 【제목키워드】 response, Decline, Pfizer–BioNTech, Month,